OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · IEX Real-Time Price · USD
1.670
+0.060 (3.73%)
Jul 22, 2024, 9:48 AM EDT - Market open
OKYO Pharma Employees
OKYO Pharma had 8 employees as of March 31, 2023. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$1,658,961
Market Cap
56.50M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 8 | 1 | 14.29% |
Mar 31, 2022 | 7 | 1 | 16.67% |
Mar 31, 2021 | 6 | 2 | 50.00% |
Mar 31, 2020 | 4 | -1 | -20.00% |
Mar 31, 2019 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
Cytosorbents | 186 |
LENSAR | 130 |
Barinthus Biotherapeutics | 130 |
Turnstone Biologics | 80 |
CollPlant Biotechnologies | 75 |
Passage Bio | 58 |
Rallybio | 43 |
OKYO News
- 11 days ago - OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 - GlobeNewsWire
- 12 days ago - OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease - GlobeNewsWire
- 2 months ago - OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) - GlobeNewsWire
- 3 months ago - OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 - GlobeNewsWire
- 3 months ago - OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery - GlobeNewsWire
- 4 months ago - OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 - GlobeNewsWire
- 4 months ago - OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial - GlobeNewsWire
- 4 months ago - OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event - GlobeNewsWire